86 related articles for article (PubMed ID: 14626239)
1. [Differences in the MLV and HIV-1 integration sites could be important for gene therapy].
Jeanteur P
Bull Cancer; 2003; 90(8-9):671. PubMed ID: 14626239
[No Abstract] [Full Text] [Related]
2. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
[TBL] [Abstract][Full Text] [Related]
3. Transcription start regions in the human genome are favored targets for MLV integration.
Wu X; Li Y; Crise B; Burgess SM
Science; 2003 Jun; 300(5626):1749-51. PubMed ID: 12805549
[TBL] [Abstract][Full Text] [Related]
4. Virology. Picking the right spot.
Trono D
Science; 2003 Jun; 300(5626):1670-1. PubMed ID: 12805525
[No Abstract] [Full Text] [Related]
5. Clinical research. Gene therapy a suspect in leukemia-like disease.
Marshall E
Science; 2002 Oct; 298(5591):34-5. PubMed ID: 12364755
[No Abstract] [Full Text] [Related]
6. Looking into the safety of AAV vectors.
Kay MA; Nakai H
Nature; 2003 Jul; 424(6946):251. PubMed ID: 12867952
[No Abstract] [Full Text] [Related]
7. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
Kang EM; Tisdale JF
Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy. What to do when clear success comes with an unclear risk?
Marshall E
Science; 2002 Oct; 298(5593):510-1. PubMed ID: 12386304
[No Abstract] [Full Text] [Related]
9. Success and setback: another adverse event.
Verma IM
Mol Ther; 2002 Nov; 6(5):565-6. PubMed ID: 12409253
[No Abstract] [Full Text] [Related]
10. Murine leukemia virus vector integration favors promoter regions and regional hot spots in a human T-cell line.
Tsukahara T; Agawa H; Matsumoto S; Matsuda M; Ueno S; Yamashita Y; Yamada K; Tanaka N; Kojima K; Takeshita T
Biochem Biophys Res Commun; 2006 Jul; 345(3):1099-107. PubMed ID: 16713998
[TBL] [Abstract][Full Text] [Related]
11. Lessons learned from gene therapy concerning and the use of integrating vectors and the possible risk of insertional oncogenesis.
Cichutek K
Dev Biol (Basel); 2006; 123():29-34; discussion 55-73. PubMed ID: 16566434
[No Abstract] [Full Text] [Related]
12. The trials of gene therapy.
Nature; 2002 Nov; 420(6912):107. PubMed ID: 12432344
[No Abstract] [Full Text] [Related]
13. Is it going to be SIN?: a European Society of Gene Therapy commentary. Phasing-out the clinical use of non self-inactivating murine leukemia virus vectors: initiative on hold.
Buchholz CJ; Cichutek K
J Gene Med; 2006 Oct; 8(10):1274-6. PubMed ID: 17001625
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy insertional mutagenesis insights.
Davé UP; Jenkins NA; Copeland NG
Science; 2004 Jan; 303(5656):333. PubMed ID: 14726584
[No Abstract] [Full Text] [Related]
15. Regulators split on gene therapy as patient shows signs of cancer.
Check E
Nature; 2002 Oct; 419(6907):545-6. PubMed ID: 12374936
[No Abstract] [Full Text] [Related]
16. Cancer fears cast doubts on future of gene therapy.
Check E
Nature; 2003 Feb; 421(6924):678. PubMed ID: 12610583
[No Abstract] [Full Text] [Related]
17. A tragic setback.
Check E
Nature; 2002 Nov; 420(6912):116-8. PubMed ID: 12432357
[No Abstract] [Full Text] [Related]
18. Cancer risk prompts US to curb gene therapy.
Check E
Nature; 2003 Mar; 422(6927):7. PubMed ID: 12621402
[No Abstract] [Full Text] [Related]
19. Second cancer case halts gene-therapy trials.
Check E
Nature; 2003 Jan; 421(6921):305. PubMed ID: 12540867
[No Abstract] [Full Text] [Related]
20. [Setback for gene therapy: Two cases of leukemia in a French trial].
Richter J; Relander T; Fasth A; Karlsson S
Lakartidningen; 2003 Feb; 100(7):498-500. PubMed ID: 12640983
[No Abstract] [Full Text] [Related]
[Next] [New Search]
